Tempest Therapeutics (TPST) Cost of Revenue (2015 - 2018)

Tempest Therapeutics has reported Cost of Revenue for 4 years, with the latest figure at $44000.0 in Q3 2018.

• Quarterly Cost of Revenue rose 51.72% year-over-year to $44000.0 in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $428000.0 (down 78.65% YoY) and the FY2017 annual result came in at $790000.0, down 85.37% from the prior year.
• Cost of Revenue slipped to $44000.0 in Q3 2018 per TPST's latest filing, from $54000.0 in the prior quarter.
• Over five years, Cost of Revenue peaked at $1.6 million in Q3 2016 and troughed at $29000.0 in Q3 2017.
• A 4-year average of $576666.7 and a median of $269000.0 in 2017 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2016 and 2017: Cost of Revenue jumped 3260.0% in 2016, then slumped 98.14% in 2017.
• Over 4 years, Cost of Revenue stood at $1.2 million in 2015, then grew by 23.75% to $1.4 million in 2016, then sank by 84.79% to $218000.0 in 2017, then plunged by 79.82% to $44000.0 in 2018.
• According to Business Quant data, Cost of Revenue over the past three periods registered $44000.0, $54000.0, and $112000.0 for Q3 2018, Q2 2018, and Q1 2018 respectively.